The ACR CRISS score was the primary efficacy endpoint of the Phase 2 study evaluating lenabasum for the treatment of diffuse cutaneous SSc.
Read More
The company will hold a conference call on Thursday, May 30, 2019, at 5:00 pm ET following the release of its first quarter 2019 financial results after market close.
Read More
The company’s overall strategy is to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.
Read More
The company published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.
Read More
The company’s largest shareholder made a selfless decision to show their belief in the future of the Company by selling shares back to MJ Holdings, Inc. at their original cost, which enabled the company to resell some of those shares for more than $5,000,000 without any dilution to its existing shareholders.
Read More
Get stock alerts, news & related alerts straight to your inbox!